Topical corticosteroids and withdrawal reactions

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued safety guidance regarding the appropriate use of topical corticosteroids and the risks associated with Topical Steroid Withdrawal (TSW). As this is a public health guidance document rather than an inspection of a specific facility, there are no specific company names or inspection dates. The regulatory framework focuses on ensuring patient safety and the correct application of various steroid potencies to prevent severe adverse reactions. The primary issues identified involve TSW, a rare but debilitating reaction occurring after prolonged or frequent use of high-potency steroids (typically over 6–12 months in adults or 2 months in children). Symptoms include intense burning, stinging, and redness extending beyond the treated area. The guidance also warns against complications from over-use, such as skin thinning, adrenal suppression, and Cushing’s syndrome, which can cause systemic issues like high blood pressure and fatigue. Required actions for patients and providers include strictly adhering to prescribed potencies, especially for sensitive areas like the face or groin. Patients must wait 20 to 30 minutes between applying emollients and topical steroids to maintain efficacy. If a condition recurs within two weeks of stopping treatment, users are advised to seek a medical review rather than self-treating. Finally, all adverse reactions should be reported to the MHRA via the Yellow Card scheme to assist in ongoing safety monitoring.